

## S 3302

Mikaela Naylor Give Kids a Chance Act of 2025

**Congress:** 119 (2025–2027, Current)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Dec 2, 2025

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Dec 2, 2025)

**Official Text:** <https://www.congress.gov/bill/119th-congress/senate-bill/3302>

### Sponsor

---

**Name:** Sen. Mullin, Markwayne [R-OK]

**Party:** Republican • **State:** OK • **Chamber:** Senate

**Cosponsors** (37 total)

<b>Cosponsor</b>	<b>Party / State</b>	<b>Role</b>	<b>Date Joined</b>
Sen. Bennet, Michael F. [D-CO]	D · CO		Dec 2, 2025
Sen. Booker, Cory A. [D-NJ]	D · NJ		Dec 2, 2025
Sen. Boozman, John [R-AR]	R · AR		Dec 2, 2025
Sen. Capito, Shelley Moore [R-WV]	R · WV		Dec 2, 2025
Sen. Collins, Susan M. [R-ME]	R · ME		Dec 2, 2025
Sen. Coons, Christopher A. [D-DE]	D · DE		Dec 2, 2025
Sen. Duckworth, Tammy [D-IL]	D · IL		Dec 2, 2025
Sen. Hickenlooper, John W. [D-CO]	D · CO		Dec 2, 2025
Sen. Husted, Jon [R-OH]	R · OH		Dec 2, 2025
Sen. Justice, James C. [R-WV]	R · WV		Dec 2, 2025
Sen. Kelly, Mark [D-AZ]	D · AZ		Dec 2, 2025
Sen. Kennedy, John [R-LA]	R · LA		Dec 2, 2025
Sen. Kim, Andy [D-NJ]	D · NJ		Dec 2, 2025
Sen. Klobuchar, Amy [D-MN]	D · MN		Dec 2, 2025
Sen. Markey, Edward J. [D-MA]	D · MA		Dec 2, 2025
Sen. Marshall, Roger [R-KS]	R · KS		Dec 2, 2025
Sen. Moody, Ashley [R-FL]	R · FL		Dec 2, 2025
Sen. Reed, Jack [D-RI]	D · RI		Dec 2, 2025
Sen. Schiff, Adam B. [D-CA]	D · CA		Dec 2, 2025
Sen. Schmitt, Eric [R-MO]	R · MO		Dec 2, 2025
Sen. Scott, Rick [R-FL]	R · FL		Dec 2, 2025
Sen. Shaheen, Jeanne [D-NH]	D · NH		Dec 2, 2025
Sen. Sheehy, Tim [R-MT]	R · MT		Dec 2, 2025
Sen. Budd, Ted [R-NC]	R · NC		Dec 9, 2025
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Dec 9, 2025
Sen. Slotkin, Elissa [D-MI]	D · MI		Dec 10, 2025
Sen. Blumenthal, Richard [D-CT]	D · CT		Dec 16, 2025
Sen. Daines, Steve [R-MT]	R · MT		Dec 16, 2025
Sen. Warner, Mark R. [D-VA]	D · VA		Dec 16, 2025
Sen. Curtis, John R. [R-UT]	R · UT		Dec 17, 2025
Sen. Fischer, Deb [R-NE]	R · NE		Dec 17, 2025
Sen. Warnock, Raphael G. [D-GA]	D · GA		Dec 17, 2025
Sen. Banks, Jim [R-IN]	R · IN		Jan 15, 2026
Sen. Heinrich, Martin [D-NM]	D · NM		Jan 15, 2026
Sen. McCormick, David [R-PA]	R · PA		Jan 15, 2026
Sen. Gallego, Ruben [D-AZ]	D · AZ		Jan 29, 2026
Sen. Van Hollen, Chris [D-MD]	D · MD		Jan 29, 2026

**Committee Activity**

<b>Committee</b>	<b>Chamber</b>	<b>Activity</b>	<b>Date</b>
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Dec 2, 2025

## Subjects & Policy Tags

---

### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
119 HR 7148	Related bill	<b>Feb 3, 2026:</b> Became Public Law No: 119-75.
119 HR 1262	Related bill	<b>Dec 2, 2025:</b> Received in the Senate.
119 S 932	Related bill	<b>Mar 11, 2025:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

### Summary (as of Dec 2, 2025)

---

#### Mikaela Naylor Give Kids a Chance Act of 2025

This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration's (FDA's) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.

Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.

The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.

The bill also renews the FDA's authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2030. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.

GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.



**Dec 2, 2025:** Introduced in Senate

- **Dec 2, 2025:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Dec 2, 2025:** Introduced in Senate
- **Dec 2, 2025:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Dec 2, 2025:** Introduced in Senate
- **Dec 2, 2025:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Dec 2, 2025:** Introduced in Senate
- **Dec 2, 2025:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Dec 2, 2025:** Introduced in Senate
- **Dec 2, 2025:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.